



Daiichi Sankyo, Inc. (DSI)

Outlook for U.S. Business for 2009


Nov. 7th, 2007

Joseph P. Pieroni


President and CEO

Daiichi Sankyo, Inc.





Largest Pharmaceutical markets



Daiichi Sankyo, Inc. - U.S. Organization




Daiichi Sankyo, Inc. – Product Portfolio

Product	Therapeutic Category	Net Sales FY 2007 (\$ million)
	Anti-Hypertension	\$756
	Dyslipidemia	\$205
	Anti-hypertensive	\$28
	Dry Mouth Syndrome	\$32
Total		\$1,021

 **Benicar**[®] TABLETS
(olmesartan medoxomil)

ARB Market

Benicar new prescription share continues to grow in ARB Market



Source: IMS National Prescription Audit (Weekly Data)

Product Pipeline


Products in late stage development

Development Stage	Product	Therapeutic Class	Key Characteristics
NDA Approved	Azor	Hypertension	<i>highly effective olmesartan combined with amlodipine</i>
NDA	WelChol*	Diabetes	<i>only product to reduce both cholesterol and glucose</i>
	prasugrel**	Acute Coronary Syndrome	<i>head to head trial versus Plavix</i>

**FDA approval expected in November 2007*

***FDA filing by year-end*

New Product Launches






Daiichi-Sankyo

 **AZOR**TM TABLETS

*amlodipine besylate
olmesartan medoxomil*

The AZOR Opportunity

amlodipine Market before patent expiration



Amlodipine + ARB Combination Market



amlodipine / valsartan (Novartis)


- Number 1 ARB combined with amlodipine
- Launched June 2007




amlodipine / olmesartan (Daiichi Sankyo)

- Fastest growing ARB combined with amlodipine
- Launched October 2007


AZOR vs. amlodipine



AZOR vs. amlodipine



AZOR vs. amlodipine




Anti-hypertensive Market

ARBs, Norvasc and Lotrel
-account for 71% of market


ARBs and Lotrel
- fastest growing classes

2006 Anti-hypertensive \$ sales



Total Sales = \$18.4 B


Sales Growth (2005 vs. 2006)



Anti-hypertensive Market

Polytherapy Growing in hypertension therapy


% of Patients on Polytherapy




Physicians using more combination therapy as a first line agent and are quicker to switch to combination therapy for patients not at goal

Azor vs. Benicar


Patient Targets



- Stage 1




- Stage 1
- Stage 2




- Predominantly Stage 2
- More Severe
- Difficult to treat
- Typically Complicated
- amlodipine & Lotrel Patients

Benicar, Azor Targets



Product Positioning





Welchol TABLETS™
(colesevelam HCl)

*NON*systemic

Welchol TABLETS
(colesevelam HCl)

Cholesterol




Welchol TABLETS™
(colesevelam HCl)


**Cholesterol
+
Diabetes**

Markets for Cholesterol and Diabetes are growing

HC Prescription Trends



Diabetes Prescription Trends



Aggressive Goals for both Cholesterol and Diabetes

Cholesterol

2007 NCEP Guidelines

LDL-C goal
In high-risk patients
(<100 mg/dL)

Current therapeutic option for
patients with CHD (<70 mg/dL):
Especially patients with diabetes


Diabetes

2007 ADA Guidelines

Patients in general
($<7\%$ A1C)

Current goal for
individual patients ($<6\%$ A1C):

As close to normal as possible



Patients Are not at Goal

Percent of people not at Goal in U.S.

Cholesterol

>50%

Diabetes

67%

Cholesterol Treatment

Increase in Combination therapy

VYTORIN[®]
(ezetimibe/simvastatin) tablets

Zetia[®]
(ezetimibe) Tablets

Welchol[™] TABLETS
(colesevelam HCl)

Niaspan[®]
niacin EXTENDED-RELEASE
TABLETS

TriCor[®] 145 mg
fenofibrate tablets & 48 mg

Diabetes Treatment

Increase in Combination Therapy

actos[®]
pioglitazone HCl


Avandia[®]
rosiglitazone maleate

Byetta[®]
exenatide injection


Januvia[™]
(sitagliptin phosphate)

Welchol Studies for Glucose lowering

Real-World Study Design



Welchol produced Consistent Reductions in A1C




*Bays H et al. Abstracts of the 16th Annual AACE Meeting & Clinical Congress; April 11-15, 2007; Seattle, WA. Abstract 204:18.

**Fonseca VA et al. Abstracts of the 16th Annual AACE Meeting & Clinical Congress; April 11-15, 2007; Seattle, WA. Abstract 409:10.

†Goldberg RB and Truitt K. Presented at: AHA Scientific Sessions 2006; November 12-15, 2006; Chicago, IL. Poster 1581.

Efficacy Expectations in Diabetes Therapy

Results of glucose lowering from recently published trials in similar patient populations



†Januvia™ (sitagliptin) Package Insert, April 2007

‡Byetta® (exenatide) Package Insert, September 2007

*Home, PD et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007 Jun;24(6):626-34

**Pooled analysis (WEL-301, WEL-302, WEL-303), Data on file, Daiichi Sankyo, Inc.

Adverse Events Concerns with Diabetic Therapy *Not Associated With Welchol™*

Typical Adverse Events	Welchol™
Increased Hypoglycemia	<i>NO</i>
Weight Gain	<i>NO</i>
Contraindications (CHF, Kidney)	<i>NO</i>
Edema	<i>NO</i>
CYP450 Interactions	<i>NO</i>



A1C + LDL-C

Two Goals One Therapy

Product Opportunities

Achieve Benicar sales of \$1 billion

With patent expiration of Norvasc, Benicar and Diovan will be the major antihypertensive drugs in U.S.

Capture significant share of ARB-amlo combo market with Azor

amlo olmesartan and amlo valsartan (Exforge-Novartis) will create a new market for ARB-amlodipine combos


Significantly increase Welchol sales with new diabetes indication

Novel approach to the treatment of diabetes plus lipid lowering


Make prasugrel a blockbuster

Success with prasugrel will make DSI a Top-Tier CV Company in U.S.

Daiichi Sankyo, Inc.



U.S. Cardiovascular Market



Long-term Strategic Objectives



Contact address regarding this material

DAIICHI SANKYO CO., LTD.
Corporate Communications Department

TEL: +81-3-6225-1126
FAX: +81-3-6225-1132

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.